Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. The end points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) according to the investigator per 2007 Response Criteria; overall survival (OS); and safety. In this final analysis, median duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% (complete response, 20.8%; partial response, 20.8%). The median DOR was not reached; no patients who achieved a complete response progressed at the data cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients (56.6%) had any-grade treatment-related adverse events (AEs); the most common were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of follow-up, pembrolizumab continued to provide durable responses, with promising trends for long-term survival and acceptable safety in R/R PMBCL.

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170 / Zinzani P.L.; Thieblemont C.; Melnichenko V.; Bouabdallah K.; Walewski J.; Majlis A.; Fogliatto L.; Garcia-Sancho A.M.; Christian B.; Gulbas Z.; Ozcan M.; Perini G.F.; Ghesquieres H.; Shipp M.A.; Thompson S.; Chakraborty S.; Marinello P.; Armand P.. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 142:2(2023), pp. 141-145. [10.1182/blood.2022019340]

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Zinzani P. L.;
2023

Abstract

Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. The end points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) according to the investigator per 2007 Response Criteria; overall survival (OS); and safety. In this final analysis, median duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% (complete response, 20.8%; partial response, 20.8%). The median DOR was not reached; no patients who achieved a complete response progressed at the data cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients (56.6%) had any-grade treatment-related adverse events (AEs); the most common were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of follow-up, pembrolizumab continued to provide durable responses, with promising trends for long-term survival and acceptable safety in R/R PMBCL.
2023
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170 / Zinzani P.L.; Thieblemont C.; Melnichenko V.; Bouabdallah K.; Walewski J.; Majlis A.; Fogliatto L.; Garcia-Sancho A.M.; Christian B.; Gulbas Z.; Ozcan M.; Perini G.F.; Ghesquieres H.; Shipp M.A.; Thompson S.; Chakraborty S.; Marinello P.; Armand P.. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 142:2(2023), pp. 141-145. [10.1182/blood.2022019340]
Zinzani P.L.; Thieblemont C.; Melnichenko V.; Bouabdallah K.; Walewski J.; Majlis A.; Fogliatto L.; Garcia-Sancho A.M.; Christian B.; Gulbas Z.; Ozcan M.; Perini G.F.; Ghesquieres H.; Shipp M.A.; Thompson S.; Chakraborty S.; Marinello P.; Armand P.
File in questo prodotto:
File Dimensione Formato  
blood_bld-2022-019340-main.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 480.06 kB
Formato Adobe PDF
480.06 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/960033
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact